-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC
The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib in comparison with placebo among patients with stage IB to IIIA NSCLC, far exceeding expectations for the global trial.1…
-
Lung Cancer Screening for Women: Understanding the Risks and the Benefits
Although science has proven that both men and women significantly benefit from lung cancer screening by low-dose CT, the NELSON study showed that women benefit substantially more than men.1 However, one of the reasons lung cancer screening is not recommended for everyone is due to the potential harm caused by the radiation exposure from low-dose…
-
Becoming a Critical Actor—Learning about Improving Equity and Inclusion in the Workplace
The recent Women in Thoracic Oncology Networking Event provided its audience with the rare opportunity to speak openly and honestly about challenges in the workforce, from microaggressions to wage gaps between men and women. Co-chaired by Drs. Narjust Duma, Clarissa Mathias, and Heather Wakelee, the event included women from all areas of thoracic oncology and…
-
LGBT Cancer Survivors and Disparities-Related Barriers That May Affect Survival
Cancer survivors who are lesbian, gay, bisexual, or transgender (LGBT) face potentially survival-limiting health disparities, and this should be addressed by the healthcare system. Those were the findings of a cross-sectional study comparing the health challenges of LGBT cancer survivors with those of survivors in the general population. Researchers hope the work will push providers…
-
Distressed Due to Pandemic, Patients with Lung Cancer Seek Educational Resources
A Canadian survey conducted repeatedly throughout the COVID-19 pandemic reflects a rise in feelings of isolation and vulnerability among patients with lung cancer. Survey results indicate that patients want educational resources that will allay their anxiety and improve their well-being, and the researchers who administered it believe that finding should guide policies and care during…
-
Practice-Changing Initiatives Benefit the Medical Team, Patients
The social and emotional needs of patients are increasingly being recognized as equally important to their physical needs, and use of multidisciplinary teams is helping to bridge the gaps between clinical and psychosocial care. The Education Session “Practice Changing Initiatives” (ES11) addressed exciting initiatives to move the field forward while helping patients become better advocates…
-
Addressing Lung Cancer Screening Disparities in the LGBT Community
Historically, sexual minorities have been underserved in the healthcare setting. Members of this patient population may be less likely to receive optimal care, especially when it comes to preventive care such as lung cancer screening—a topic that was discussed during the Mini Oral Abstract Session “MA04: Health Policy and the Real World.” The older (between…
-
Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors
Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the treatment of these diseases. As part of Friday’s Plenary session “PL03: Bench to Bedside (Immunology),” Prasad S. Adusumilli, MD, FACS, attending and deputy chief of…
-
Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation
With no approved treatments for advanced NSCLC with EGFR exon 20 insertion mutations, treatment is mainly limited to chemotherapy, as these cancers don’t respond to traditional tyrosine kinase inhibitors (TKIs). But previously treated patients with this rare subtype responded to mobocertinib, with a manageable safety profile, in a phase I/II trial discussed during (OA04: New…
-
More Data Needed on Benefit of Adaptive Radiation Approaches in Locally-Advanced NSCLC
The results of one phase II study looking at PET/CT-guided adaptive radiation therapy and one PET boost trial in locally advanced NSCLC were presented in an Oral Abstract Session (OA2). Previously published, long-term results of the ROTG 0617 trial showed that high-dose (74 Gy given in 2 Gy daily fractions that prolonged overall treatment time)…